topotecan has been researched along with Hypoxia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruick, RK; Hossain, CF; Mohammed, KA; Nagle, DG; Zhang, L; Zhou, YD | 1 |
| Kao, G; Xiao, J; Xu, Y; Yan, M; Zhang, Y; Zhou, K | 1 |
| Eschenko, N; Galkina, O; Lomert, E; Lyanguzov, A; Nimiritsky, P; Rybnikova, E; Sarieva, K; Tyulkova, E; Vetrovoy, O | 1 |
| de Lange, J; Jager, MJ; Jochemsen, AG; Lodder, K; Ly, LV; Teunisse, AF; Verlaan-de Vries, M | 1 |
| Hansen, LT; Kristjansen, PE; Lund, EL | 1 |
5 other study(ies) available for topotecan and Hypoxia
| Article | Year |
|---|---|
Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Diterpenes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mitochondria; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Rhodophyta; Stereoisomerism; Transcription Factors | 2004 |
Hypoxia-inducible transcription factor-1α inhibition by topotecan protects against lipopolysaccharide-induced inflammation and apoptosis of cardiomyocytes.
Topics: Apoptosis; Humans; Hypoxia; Inflammation; Lipopolysaccharides; Myocytes, Cardiac; Topotecan; Transcription Factors | 2021 |
Pharmacological HIF1 Inhibition Eliminates Downregulation of the Pentose Phosphate Pathway and Prevents Neuronal Apoptosis in Rat Hippocampus Caused by Severe Hypoxia.
Topics: Animals; Apoptosis; Down-Regulation; Hippocampus; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Neurons; Pentose Phosphate Pathway; Rats; Rats, Wistar; Topotecan | 2020 |
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; Furans; Humans; Hypoxia; Imidazoles; Melanoma; Melanoma, Experimental; Mice; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uveal Neoplasms | 2012 |
Augmenting tumor sensitivity to topotecan by transient hypoxia.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Small Cell; Cell Hypoxia; Cell Line, Tumor; Central Nervous System Neoplasms; Glioblastoma; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Topotecan; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |